NEW YORK, NY / ACCESSWIRE / July 28, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District, Southern District of New York, on behalf of those who purchased shares of Inovalon Holdings, Inc. (“Inovalon” or the “Company”) (NASDAQ: INOV), pursuant or traceable to the Registration Statement and Prospectus (collectively, the “Registration Statement”) issued in connection with Inovalon’s February 12, 2015 initial public offering (“IPO”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

Inovalon is a technology company based in Bowie, Maryland. It uses cloud-based analytics and technology to help clients achieve insights that approve clinical and quality outcomes, utilization and financial performance in the healthcare industry.

In February, 2015, Inovalon issued over 25 million shares of its common stock for $27 per share, raising over $684 million in gross proceeds.

The complaint alleges that the Registration Statement released in connection with the IPO contained falsified statements and omitted to state material facts required by governing regulations and necessary for investors to make an informed decision. Defendants failed to disclose that Inovalon makes a large percentage of its revenue from sales in the City of New York and the State of New York, both of which were restructuring their corporate tax schemes in order to capture more taxes from out-of-state businesses like Inovalon doing substantial business within their borders. The corporate tax rate increased, effective January 1, 2015, which was more than a month prior to Inovalon’s IPO, significantly inflated Inovalon’s effective tax rate, lowering its 2015 revenue potential. This information should have been included in the Registration Statement but were not. The Registration Statement claimed that Inovalon’s year-over-year “effective income tax rate…remained relatively stable at 39%.”

Once this information was made public, Inovalon stock dropped. At the time of the filing of the complaint, Inovalon shares were trading below $18 per share, or roughly 33% below the IPO price.

No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/#!inov/kk5vc. You can also contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Inovalon, you have until August 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441682

NEW YORK, NY / ACCESSWIRE / July 28, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Halyard Health, Inc. (“Halyard” or the “Company”) (NYSE: HYH) and Kimberly-Clark Corporation (“Kimberly-Clark” or the “Company”) (NYSE: KMB) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and is on behalf of a class consisting of all persons other than Defendants who: (1) purchased or acquired Kimberly-Clark securities on or after February 25, 2013 and consequently received Halyard shares pursuant to Kimberly-Clark’s spin-off of Halyard, effective as of October 31, 2014; and/or (2) purchased or acquired Halyard securities between October 21, 2014 and April 29, 2016, both dates inclusive (collectively, the “Class Period”).

This case seeks to recover damages caused by the Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder.

Halyard Health, formerly Kimberly-Clark Health Care is a global medical manufacturer based in Alpharetta, Georgia. The Company operates through two divisions, Surgical and Infection Prevention (S&IP), and Medical Devices.

Halyard was the Health Care operating segment of Kimberly-Clark before October of 2014. Kimberly-Clark manufactured personal care, consumer tissue, and professional products. On October 7, 2014, Kimberly-Clark revealed the details for the spin-off of its Health Care segment as Halyard Health, Inc., guiding investors that they would receive one share of Halyard Health stock for every eight shares of Kimberly-Clark stock held on October 23, 2014.

In late 2013, the Ebola virus outbreak began in Guinea and spread to Liberia, Sierra Leone, and other West African nations. In August 2014 the World Health Organization labeled the outbreak as a Public Health Emergency of International Concern, invoking legal measures on disease prevention, surveillance and control. On September 30, 2014, the United States Centers for Disease Control and Prevention announced the first case of Ebola virus in the United States.

As the Ebola epidemic grew, the demand for personal protective equipment like eye shields, face masks and disposable gowns grew. Kimberly-Clark’s Health Care segment and Halyard, manufactured the MICROCOOL surgical gowns.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Particularly, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s MICROCOOL surgical gowns constantly failed its tests to meet industry standards; (2) Kimberly-Clark and Halyard knew of the defects and still provided MICROCOOL surgical gowns to U.S. workers during the Ebola crisis; and (3) consequently, Defendants’ public statements were materially false and misleading at all relevant times.

On May 1, 2016, 60 Minutes announced that Kimberly-Clark and Halyard had knowledgeably provided faulty and unreliable surgical gowns to U.S. workers during the Ebola crisis. A Company insider stated that these MICROCOOL gowns would leak and did not meet the safety standards for Ebola, and still Kimberly-Clark and Halyard “aggressively” promoted and sold the MICROCOOL gowns to hospitals at the height of the Ebola epidemic.

Following this news, Halyard stock dropped $1.21, or 4.3%, to close at $26.95 per share on May 2, 2016.

A class action lawsuit has already been filed. If you have incurred a loss of over $100,000 and wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/#!hyhkmb/dtdqc or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Haylard and/or Kimberly-Clark you have until August 29, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441812

NEW YORK, NY / ACCESSWIRE / July 28, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ambac Financial Group, Inc. (“Ambac” or the “Company”) (NASDAQ: AMBC) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, is on behalf of a class consisting of all persons or entities who purchased Ambac securities between November 13, 2013 through June 30, 2015, inclusive (the “Class Period”).

The Complaint alleges that throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Ambac had far greater losses and loss exposure to anticipated defaults than it had previously disclosed in its public finance bond portfolio; (2) Ambac’s credit risk surveillance strategies were insufficient; (3) Ambac was failing to implement mitigation strategies in a timely manner to stabilize the residual value of its financial guarantee business; (4) consequentially, Ambac’s financial condition was much worse than represented; and (5) Ambac failed to maintain adequate internal controls over financial reporting. Due to the defendants’ alleged false and misleading statements, Ambac’s stock traded at artificially inflated prices during the Class Period, and investors were damaged once the true details were made public.

According to the Complaint, on June 29, 2015, the governor of Puerto stated that the island’s debt of over $70 million was “not payable” and Puerto Rico would soon be unable to pay its upcoming interest payments. This declaration exposed Ambac’s potential liability of up to $2.5 billion of the Commonwealth’s debt it insures. Following this news, Ambac dropped $6.47 per share or 28.9%, on July 1, 2015.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/#!ambc/u06xx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Ambac you have until August 29, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442032

NEW YORK, NY / ACCESSWIRE / July 28, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court District of New Jersey on behalf of those who purchased shares of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM) and certain of its officers, during the period between March 18, 2013 and June 8, 2016, inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The complaint alleges that Defendants violated Sections 10(b), 14(e) and 20(a) of the Securities Exchange Act of 1934.

Insmed, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapies for patients with serious lung diseases. ARIKAYCE™ (Liposomal Amikacin for Inhalation, or LAI), Insmed’s lead product candidate, is an investigational drug comprising the antibiotic amikacin in the Company’s proprietary liposomal technology formulation. ARIKAYCE is in late-stage clinical development for treatment of serious lung infections such as those caused by nontuberculous mycobacteria (NTM), through delivery of antibiotic directly to the site of the lung infection.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Particularly, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the data supporting Insmed’s European marketing authorization application (“MAA”) for Arikayce was not likely to be approved by the European Medicines Agency (“EMA”) for the treatment of NTM lung disease; (2) Arikayce’s endorsement by the EMA for the treatment of NTM lung disease and subsequent commercialization in Europe were therefore not as likely than Insmed had led its investors to believe; and (3) consequentially, Insmed’s public statements were materially false and misleading at all relevant times.

On June 8, 2016, post-market, Insmed revealed that it had removed Arikayce’s treatment of NTM lung disease MAA from the EMA. Insmed said, “During the May 2016 Committee for Medicinal Products for Human Use (CHMP) meeting, the CHMP indicated that the phase 2 study did not provide a sufficient amount of evidence to support an approval. Insmed intends to resubmit its MAA when clinical data from its ongoing global phase 3 study are available.” Following this news, Insmed stock dropped $0.99 per share, or 8.24% to close at $11.02 on June 9, 2016.

No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/#!insm/iz8zm or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Insmed, you have until September 13, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442519

IRVINE, CA / ACCESSWIRE / July 28, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit was filed against TransEnterix, Inc. (“TransEnterix” or the “Company”) (NYSE MKT: TRXC). Investors who purchased or otherwise acquired shares between February 10, 2016 and May 10, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the August
1, 2016 lead plaintiff motion deadline.

If you purchased shares of TransEnterix during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that, throughout the Class Period, TransEnterix made false and misleading statements and/or failed to disclose that: there were deficiencies within the Company’s 510(k) submission regarding the SurgiBot that undermined the likelihood that the SurgiBot would receive clearance from the Food and Drug Administration, which would leave TransEnterix unable to commercialize the SurgiBot in 2016, and would impair the Company’s ability to obtain approval for and commercialize its other robotic surgery platform in the United States.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 442958

LOS ANGELES, CA / ACCESSWIRE / July 28, 2016 / Lundin Law PC announces a class action lawsuit has been filed against Oracle Corporation (“Oracle” or the “Company”) (NYSE: ORCL) concerning possible violations of federal securities laws between September 16, 2015 and June 1, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 1, 2016 lead plaintiff motion
deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the complaint, the Company made materially false and misleading statements to investors and/or failed to disclose that Oracle used improper accounting methods to inflate the Company’s cloud computing revenues; and that the Company violated the law when terminating senior finance manager Svetlana Blackburn for raising the Company’s improper accounting practices to the attention of supervisors. As a result of the above, Oracle’s public statements were materially false and misleading at all relevant times. On June 1, 2016, the media reported that Ms. Blackburn sued the Company for her termination. When this news was announced, shares of Oracle fell in value.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 442959

VANCOUVER, BC / ACCESSWIRE / July 28, 2016 / Orestone Mining Corp. (TSXV: ORS) is pleased to announce that the Company has initiated a geophysical survey over the Admiral target on the Company’s 100 percent owned Captain copper-gold porphyry project in North Central British Columbia. The program, budgeted at CDN$25,000, will consist of eight line kilometers of IP/Resistivity and continuous detailed ground magnetics to be completed and analysed during August.

The Admiral target is a large magnetic high measuring 1000 metres by 1500 metres with very little geophysical information available to guide future drilling. The focus of the survey is to refine the size and shape of the target prior to drilling. The IP/Resistivity survey will be conducted on four 2.0 kilometer lines spaced 400 meters apart with readings taken every 100 meters. The magnetic survey will consist of continuous detailed ground magnetics on the grid layout described above.

The last hole drilled on the project in 2013, Hole C13-03, intersected three meters of highly potassic-sericite altered monzonite porphyry which assays 0.226% copper and 1.90 g/t gold over three metres in an otherwise unaltered and un-mineralized post mineral alkali gabbro dyke. This is interesting because the xenolith fragment or rafted block is thought to have been transported from immediate adjacent rocks.

The monzonite porphyry xenolith fragment has abundant sulphides and will have a “strong IP signature” associated with it while the unaltered and un-mineralized post mineral alkali gabbro dyke that runs through it has few sulphides or a “weak IP signature”.

Gary Nordin, P. Geo., a director of Orestone Mining Corp., is a qualified person under the NI 43-101 guidelines and has reviewed the technical content of this news release.

The 100 percent owned Captain Project hosts a large gold-copper porphyry system measuring seven by fourteen kilometers located 41 kilometers north of Fort St. James, British Columbia and approximately 30 kilometers south of the Mt. Milligan copper-gold Mine. The project features relatively flat terrain, moderate tree cover and an extensive network of logging and Forest Service roads suitable for exploration year around. The Company now has all permits in place to facilitate 75 line kms of geophysics with 58 sites approved for drilling. Further information on this will be announced at a later date.

Orestone Mining Corp. is a Canadian based company that controls a portfolio of gold-copper exploration targets in British Columbia, Canada. For more information please visit: www.orestone.ca.

ON BEHALF OF ORESTONE MINING CORP.

“David Hottman”

President and CEO
604.629.1929

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this News Release. This news release has been prepared by management and no regulatory authority has approved or disapproved the information contained herein.

SOURCE: Orestone Mining Corp.

ReleaseID: 442957